NanoSpot.ai is leveraging a blood-spot-based (hemagglutination) approach and an artificial intelligence-driven mobile application to provide low-cost, accurate, objective, instrument-free, and quantitative diagnostic results to the point of care/home environment. We have now commercialized our first test on the platform for SARS-CoV-2 Total Antibodies and are actively developing several additional indications that we believe will disrupt some of the largest markets in PoC/home-based diagnostics.
Additional Info
We will be displaying a new product or promoting a new indication/enhanced feature for an existing product in our booth?
YesIncluded in the Export Interest Directory?
YesBusiness Needs:
Distributor/Agent/Representative, Investor, Joint Ventures, Licensing Agreements